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Abstract
Epidermal growth factor receptor (EGFR) signaling is strongly implicated in glioblastoma (GBM) tumorigenesis. How-
ever,molecular agents targeting EGFRhave demonstratedminimal efficacy in clinical trials, suggesting the existence
of GBM resistance mechanisms. GBM cells with stem-like properties (CSCs) are highly efficient at tumor initiation
and exhibit therapeutic resistance. In this study, GBMCSC lines showed sphere-forming and tumor initiation capacity
after EGF withdrawal from cell culture media, compared with normal neural stem cells that rapidly perished after
EGF withdrawal. Compensatory activation of related ERBB family receptors (ERBB2 and ERBB3) was observed in
GBM CSCs deprived of EGFR signal (EGF deprivation or cetuximab inhibition), suggesting an intrinsic GBM resis-
tancemechanism for EGFR-targeted therapy. Dual inhibition of EGFR and ERBB2with lapatinib significantly reduced
GBM proliferation in colony formation assays compared to cetuximab-mediated EGFR-specific inhibition. Phosphor-
ylation of downstream ERBB signaling components (AKT, ERK1/2) and GBM CSC proliferation were inhibited by
lapatinib. Collectively, these findings show that GBM therapeutic resistance to EGFR inhibitors may be explained
by compensatory activation of EGFR-related family members (ERBB2, ERBB3) enabling GBM CSC proliferation,
and therefore simultaneous blockade of multiple ERBB family members may be required for more efficacious
GBM therapy.
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Introduction
Patients diagnosed with the brain cancer, glioblastoma (GBM), have a
poor median survival of 14 months despite aggressive surgery, radia-
tion, and chemotherapy [1,2]. Aberrant receptor tyrosine kinase
(RTK) signaling is found in approximately 88% of GBMs [3]. In par-
ticular, the epidermal growth factor receptor (EGFR) is amplified or
mutated in approximately half of GBMs, with 20% of tumors expres-
sing the constitutively active mutant EGFRvIII protein [3–5]. En-
hanced EGFR signaling in GBM leads to increased proliferation,
survival, and invasion of tumor cells via downstream AKT and
ERK1/2 signaling [4,6–9] andmay be critical for GBM tumorigenesis.
Because abnormal EGFR signaling is implicated in GBM and many
other cancers, EGFR-targeting agents such as small-molecule tyrosine
kinase inhibitors (TKIs, such as gefitinib, erlotinib, and lapatinib) and
monoclonal antibodies (such as cetuximab and pertuzumab) have been
developed for potential clinical use [10–12]. Unfortunately, clinical
trials using EGFR inhibitors demonstrated onlymodest improvements
in a small percentage of GBM patients [13–16], suggesting that many
GBMs have intrinsic or rapidly acquire resistance to EGFR inhibition.
The cancer stem cell (CSC) theory posits that a small subpopulation
of self-renewing “stem-like” cancer cells drives tumor propagation and
recurrence [17,18]. CSCs have been isolated from GBM through AC/
CD133 expression [19,20] or by sphere culture in stem cell medium
[21–24] and are highly efficient at initiating phenocopies of the human
neoplasm as xenografts forming with injection of as few as 102 to 103
CSCs into brains of immunodeficient mice [24,25]; if the injected
tumor cells are first depleted of CSCs, cancer rarely develops [19].
In addition, GBM CSCs demonstrate resistance to commonly used
anticancer therapies such as radiation [20] and chemotherapy
[26,27]. Therefore, the current hypothesis is that therapeutically resis-
tant GBM CSCs contribute to the observed rapid GBM recurrence
resulting in poor patient survival, and therefore, CSC elimination is
critical for effective therapies.
We hypothesized that GBM CSCs are involved in resistance to
EGFR-specific inhibition. Supporting this hypothesis, Kelly et al.
[25] demonstrated CSC propagation in the absence of exogenous
growth factors (EGF and basic fibroblast growth factor [bFGF]), sug-
gesting that these RTK signaling pathways may not be critical for
GBM CSCs. However, confounding data are reported by other
groups, which show that EGFR signaling is required for GBM CSC
proliferation [28,29] and that addition of EGFR-specific inhibitors
significantly decreased the sphere-forming and growth potential of ex-
ogenous growth factor–independent GBM CSCs [25]. In this study,
we establishedmultiple independent GBMCSC lines in the absence of
exogenous mitogens (EGF and bFGF) to uncover and analyze poten-
tial resistance mechanisms of GBM CSCs to anti-EGFR therapies.
GBM CSCs continued to proliferate as spheres in the absence of ex-
ogenous EGF and bFGF and retained tumor-initiating capability. We
discovered that downstream activation of AKT and ERK pathways was
maintained in GBM CSCs grown without exogenous mitogens,
through activation of other EGFR-related receptor family members in-
cluding ERBB2/HER2/neu and ERBB3/HER3. Lapatinib-mediated
multireceptor inhibition of EGFR and ERBB2 was significantly more
effective at preventing GBM CSC proliferation in colony formation
assays compared with cetuximab-targeted inhibition of EGFR alone.
Lapatinib treatment decreased downstream AKT and ERK activation
in multiple independently derived GBM CSC lines. These results
show that monotherapy against EGFR probably failed clinically for
GBM because a subset of GBM cells are able to activate downstream
signaling through related ERBB family members (ERBB2, ERBB3).
Therefore, targeting of multiple ERBB family members is needed to
overcome such resistance mechanisms and potentially achieve better
clinical outcomes.
Materials and Methods
Isolation of GBM CSCs
All studies involving human tissue were performed with approval
from the University of Wisconsin – Madison institutional review
board with informed consent obtained from patients. GBM CSCs
were isolated following protocols previously reported [21,23,30,31],
with a few modifications. Tumor tissue was collected directly from
the operating room, weighed, coarsely minced with a scalpel blade,
and subsequently chopped twice at 200 μm using a tissue chopper
(Sorvall TC-2 Smith-Farquahar). Chopped tissue was directly plated
in suspension at 10 mg/ml in growth medium (passage medium [PM]:
70% Dulbecco modified Eagle medium–high glucose, 30% Ham’s
F12, 1× B27 supplement, 5 μg/ml heparin, penicillin-streptomycin-
amphotericin (PSA), and 20 ng/ml each of EGF and bFGF) [30]. Cul-
tures were passaged approximately every 7 to 10 days by tissue chopping
twice at 200 μm. For initial studies, we used three different GBM CSC
cell lines: two from primary (22 and 33) and one from recurrent (12.1)
GBM. For later studies, additionalGBMCSC lines were isolated through
sphere culture (44 CSC) or growth on laminin substrates (15 and
99 CSC) [32]. Photomicrographs were taken using a Nikon Eclipse
TE-2000 microscope (Nikon Instruments, Melville, NY) running
MetaMorph 7.2 software. In all studies, GBM CSCs were compared
to normal neural stem cells (NSCs). Human cortex fetal NSCs were a
kind gift from Dr Clive Svendsen and were maintained as previously
described [30].
Immunofluorescent Staining
Primary and secondary antibodies were purchased commercially:
βIII-tubulin (G712A; Promega, Madison, WI); human nuclei (HuNu,
MAB1281; Chemicon, Temecula, CA), CD(AC)133 (130-090-422;
Miltenyi Biotec, Auburn, CA); nestin (ab5968), glial fibrillary acidic
protein (GFAP; ab7779), and EGFR (ab52894) (all from Abcam,
Cambridge, MA); and goat anti-IgG secondary antibodies Alexa Fluor
488 and 568 (Invitrogen, Grand Island, NY).
Medium-sized GBM CSC spheres (≈200-300 μm diameter) were
seeded into eight-well chamber slides and incubated at 37°C for either
3 hours to test for stem cell markers and EGFR expression or 7 days in
growth factor–depleted medium (minus EGF and bFGF) to test for
glial (GFAP) and neuronal (βIII-tubulin) lineages. After incuba-
tion, cells were immediately fixed in 4% paraformaldehyde,
blocked/permeabilized in 10% goat serum + 0.5% bovine serum albu-
min + 0.4%Triton X-100, and stained for 1 hour at room temperature
with the following primary antibodies: anti–human nuclei (1:100),
nestin (1:250), βIII-tubulin (1:2000), GFAP (1:1000), or EGFR
(1:250). Fluorescent secondary antibodies (Alexa Fluor 488 or 568,
1:200) were then added for 1 hour at room temperature. Slides were
then mounted with Prolong Gold with 4′,6-diamidino-2-phenylindole
(DAPI; nuclear stain; Invitrogen). Fluorescent images were collected
using epifluorescence (Nikon Eclipse TE-2000 microscope running
MetaMorph 7.2 software) using appropriate filters. Normal NSCs
were used as controls for all staining, and staining without primary
antibody was performed as a control for nonspecific binding.
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Flow Cytometry of Live Cells for Membrane Proteins
Antibodies EGFR (ab82194; Abcam) and CD(AC)133 preconju-
gated to R-PE (phycoerythrin) (130-080-801; Miltenyi Biotec) were
used for flow cytometry. Secondary goat anti-IgG antibodies labeled
with R-PE were purchased from Invitrogen.
GBM CSCs were dissociated with an enzyme-free cell dissociation
buffer (Invitrogen), and approximately 106 cells were resuspended in
flow cytometry buffer (PBS + 1% goat serum). For preconjugated
CD133-R-PE (1:11), cells were incubated on ice for 1 hour and rinsed.
For anti-EGFR antibody (1:50), cells were first incubated on ice for
1 hour with primary antibodies before rinsing and 1 hour of incuba-
tion on ice with species-specific secondary antibodies conjugated to
R-PE (1:50). GBM CSCs were then analyzed using flow cytometry
(FACScalibur; BectonDickinson, Franklin Lakes, NJ). Isotype controls
that received only secondary antibody to exclude nonspecific binding
events and propidium iodide to determine live cells were used to
gate data, which was analyzed using WinMDI freeware (http://facs.
scripps.edu/software.html). A minimum of two independent experi-
ments with duplicate samples (total n = 4) were performed; if results
demonstrated high variability, a third independent experiment with
duplicate samples was carried out.
Semiquantitative Reverse Transcription–Polymerase Chain
Reaction for EGFRvIII Mutation
Presence of the EGFRvIII mutation in GBMCSCs was tested using
reverse transcription–polymerase chain reaction (RT-PCR), using pri-
mers for EGFR/EGFRvIII as previously described [28]. Amplification
conditions were 94°C for 2 minutes, followed by 42 cycles of denatur-
ation at 95°C for 30 seconds, annealing at 56.5°C for 30 seconds, and
extension at 68°C for 90 seconds. GAPDH functioned as housekeeping
control with primers (forward, ACCACAGTCCATGCCATCAC; and
reverse, TCCACCACCCTGTTGCTGTA); amplification conditions
were 94°C for 2 minutes, followed by 24 cycles of denaturation at
95°C for 30 seconds, annealing at 57°C for 30 seconds, and extension
at 68°C for 90 seconds.
GBM CSC Orthotopic Xenograft Model
Tumor initiation capacity of GBM CSCs under various conditions
was verified by orthotopic xenograft as previously described [19,21,22],
under a protocol approved by the Institutional Animal Care and Use
Committee at UW-Madison. Briefly, GBM CSCs were enzymatically
dissociated to single cells, and varying cell numbers (102-106) were sus-
pended in 5 μl of PBS. Using a Hamilton syringe, the cells were stereo-
tactically injected into the right striatum of anesthetized nonobese
diabetic severe combined immunodeficient mice at 0.33 μl/min at the
following coordinates referenced from bregma: 0 mm anteroposterior,
+2.5 mm mediolateral, and −3.5 mm dorsoventral [22]. At either
3 months or onset of neurological symptoms, tumor formation was ver-
ified using magnetic resonance imaging (MRI).Mice were anesthetized,
contrast enhanced using 10 mmol/kg of intraperitoneal gadodiamide
[33] (Omniscan; GE Healthcare, Piscataway, NJ), and placed onto a
small animalMRI scanner (4.7-T horizontal bore imaging/spectroscopy
system; Varian , Palo Alto, CA), and T1- and T2-weighted images were
obtained. As per animal protocol, once MRI showed tumor xenograft
growth or when neurological symptoms were observed, injected nonobese
diabetic severe combined immunodeficient mice were immediately
euthanized by perfusion fixation with 4% paraformaldehyde, even if
the animals were asymptomatic. Brains were then excised, embedded
in paraffin, and processed for general histology.
Proliferation Assay
To test effects of exogenous mitogen withdrawal on short-term pro-
liferation, 20,000GBMCSCs were plated into 96 wells and allowed to
proliferate for 4 days in respective medium +EGF/+bFGF or −EGF/
−bFGF. Cell number was quantified using MTS assay, as per the
manufacturer’s instructions (CellTiter 96 AQueous Non-Radioactive
Cell Proliferation Assay; Promega).
Colony-Forming Assay
Cetuximab was purchased from Bristol-Myers Squibb (Princeton, NJ).
Lapatinib, gefitinib, and erlotinib were purchased from LC Laborato-
ries (Woburn, MA). Pertuzumab was kindly provided by Genentech
(San Francisco, CA). Doses used for gefitinib, erlotinib, cetuximab, and
pertuzumab were determined from the literature as 50% inhibiting con-
centrations for head and neck cell lines [34,35]. Lapatinib dose was chosen
as reported as the 50% inhibiting concentration for glioma cell lines [36].
GBM CSCs were enzymatically dissociated to single cells and seeded
at 2000 cells/well into six-well plates precoated with poly-L-lysine/
laminin. After cell recovery overnight, medium was exchanged with
drug-containing medium, and afterward, fresh media containing drug
were added twice a week. When GBM CSC colonies (>50 cells) became
visible (≈2-4 weeks), cells were fixed and stained with 0.5% crystal violet
in methanol for 5 minutes and rinsed extensively with distilled water.
Colonies were then manually counted, with drug-treated conditions
normalized to vehicle controls.
Immunoblot Analysis
Immunoblot analysis was performed as previously described [34], with a
fewmodifications. The following antibodies were used: EGFR (sc-03),
ERBB2/HER2/neu (sc-284), pERBB2 (Y1248) (sc-12352R), and
ERBB3/HER3 (sc-285) were fromSantaCruz Biotechnology (SantaCruz,
CA); pERBB3 (Y1197) (4561), AKT (4691), pAKT (S473) (4060),
ERK1/2 (4696), and pERK1/2 (Thr202/Tyr204) (9106), and α-tubulin
(3873) from Cell Signaling Technology (Beverly, MA); pEGFR (Y1068)
(ab32430) from Abcam; HRP-conjugated goat–anti-rabbit IgG (32460)
and goat–anti-mouse IgG (32430) were purchased fromThermo Scientific
(Waltham, MA).
For immunoblot analysis studies, GBM CSCs with and without ex-
ogenous mitogens were lysed using cell extraction buffer (FNN0011;
Invitrogen) containing protease inhibitor cocktail (P8340; Sigma-
Aldrich, St Louis, MO). Protein was quantified using a fluorescent-based
total protein assay (EZQ Protein Quantitation, R33200; Invitrogen).
Proteins (10 μg) were resuspended in 2× reducing sample buffer (Novex,
LC2676; Invitrogen), electrophoresed on 10% to 20% Tris-glycine gels
(Invitrogen), transferred using a semidry transfer system (Biorad,Hercules,
CA) to polyvinylidene difluoride membranes (Millipore, Billerica, MA),
and probed with specific antibodies. Detection of immunocomplexes
was accomplished using luminescence (SuperSignal West Femto Maxi-
mumSensitivity Substrate; Thermo Scientific), as per themanufacturer’s
instructions. For drug-related biochemical tests, exogenous growth
factors were removed overnight from GBM CSCs. Drugs were then
added to medium 2 hours before stimulation with EGF for 30 minutes,
and GBM CSCs were collected and immunoblotted as above.
Results
Isolation and Validation of GBM CSC Lines
Cancer stem–like cell lines were successfully isolated from multiple
patient GBM specimens using standard procedures. After approximately
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2 to 4 weeks, small spheres were observed in culture, which continued
to propagate in suspension (Figure 1). In our laboratory, the GBM
CSCs propagated faster by passaging using the chopping technique
used for some normal human NSC cultures [30], compared to passag-
ing through mechanical dissociation, and were passaged every 7 to
10 days. Four independent GBM CSC lines were isolated through
sphere culture: three from newly diagnosed (22, 33, 44) and one from
a first recurrence (12.1). Two additional lines (15 and 99) were isolated
through culture on laminin substrate using identical media conditions
[32], and GBMCSCs isolated by either method exhibit similar genetic
and phenotypic behaviors [32,37]. The three GBM CSC lines 12.1,
22, and 33 were chosen for most experiments. All GBM CSC lines
expressed stem cell markers (CD133, nestin), detected by immunocy-
tochemistry (Figure 1), and after removal of the mitogenic factors EGF
and bFGF and attachment to poly-L-lysine/laminin–coated dishes, the
GBM CSC differentiated and expressed markers of both glial (GFAP)
and neuronal (βIII-tubulin) lineages, demonstrating their multilineage
potential (Figure 1). Flow cytometry independently confirmed the uni-
form enrichment of GBMCSCs with CD133 expression (Figure 1), an
NSC marker used in other published GBM CSC studies [19,31]. Im-
portantly, the GBM CSCs also efficiently initiated orthotopic xeno-
graft tumors within 12 to 16 weeks after injection of 2 × 105 GBM
CSCs, as visualized by MRI and histology (Figure 1). Injection of
102 to 103 GBM CSCs initiated tumors (Table W1). GBM CSC xe-
nografts were observed to recapitulate parental GBM phenotypes of
diffusely infiltrating tumor cells, vascular proliferation, and areas of
necrosis, although not all features were present for eachGBMCSC line
derived xenograft (Figures 1 and W1). This is in contrast to tumor
models derived from injection of standard laboratory glioma cell lines,
which yield discrete xenografts only with a high number of injected
cells (>106 cells) [21]. No tumor xenografts were found in mice in-
jected with an equal number of normal human NSCs after 6 months.
GBM CSCs Express EGF Signaling Components
Although growth factors such as EGF and bFGF are required for
continued expansion of normal NSCs, GBMCSCs may have aberrant
signaling mechanisms that allow them to escape normal regulation by
these factors, similar to that described by Kelly et al. [25]. Immunocyto-
chemistry demonstrated abundant and widespread EGFR expression
in both GBM CSCs and human fetal NSCs (Figure 2, A and B); im-
munocytochemical staining results were also verified using immuno-
blot analysis (Figure 2C ). The percentage of GBM CSC cells
expressing EGFR as well as EGFR expression intensity was determined
using flow cytometry (Figure 2E ). Interestingly, NSCs exhibited sig-
nificantly higher (≈4 times more EGFR+ cells and≈2 times higher
intensity) EGFR expression thanGBMCSCs did (Figure 2F ; P < .05).
The expression of the constitutively active, mutant EGFRvIII was not
observed in GBM CSCs or in NSCs using semiquantitative RT-PCR
(Figure 2D) [28].
GBM CSCs Are Maintained after Exogenous EGF Removal
and Activate ERBB Family Signaling
We next determined the exogenous EGF requirement for GBM
CSCs and possible compensationmechanisms in the absence of EGFR
activation. For all tested GBMCSC lines as well as control NSCs, pro-
liferation after 4 days was significantly reduced after removal of exoge-
nous mitogens (Figure 3A; P < .05). However, NSCs exhibited a much
greater reduction compared to the GBM CSC lines (NSC: +EGF/
+bFGF = 100% ± 4.4%, −EGF/−bFGF = 29% ± 11%; 12.1:
+EGF/+bFGF = 100% ± 11%, −EGF/−bFGF = 73% ± 11%;
22: +EGF/+bFGF = 100% ± 6.5%, −EGF/−bFGF = 79% ± 11%;
33: +EGF/+bFGF = 100% ± 7.4%, −EGF/−bFGF = 73% ±
6.5%; −EGF/−bFGF values normalized to +EGF/+bFGF values),
and small spheres were only observed in GBMCSCs in −EGF/−bFGF
conditions. In long-term culture, all GBM CSC lines continued to
proliferate as spheres after exogenous mitogen removal (Figure 3B), al-
though at a slower observed rate. Normal NSCs cultured under similar
conditions failed to propagate. After adaptation for a minimum of
2 months with normal expansion and passaging, GBM CSC lines
grown without exogenous mitogens were analyzed for stem cell, multi-
lineage, and tumor-initiating properties. GBM CSCs without exoge-
nous mitogens maintained expression of the stem cell marker nestin
Figure 1. Characterization of GBMCSCs. Sphere-forming GBMCSCs from surgical specimens were obtained after 2 to 4 weeks of culture
in stem cell medium (A) that expressed NSC markers (B: CD133, green; DAPI nuclear counterstain, blue; C: nestin, green) and demon-
strated multilineage potential (D: βIII-tubulin/Tuj1, green; GFAP, red). Enrichment for CD133 was verified using flow cytometry (G). GBM
CSCs initiated tumors 12 to 16 weeks after orthotopic injection, as evidenced by MRI (E: 22 GBM CSCs, 100,000 cells, 106 days after
injection; T1-weighted with gadolinium enhancement) and histology (F: hematoxylin and eosin). T indicates tumor.
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(Figure 3C ), multilineage potential (Figure 3D), and tumor-initiating
capacity in immunodeficientmice (Figures 3E andW1). Sphere-forming
GBMCSCswere also recovered from xenografts that exhibited stem cell
marker expression and multilineage potential (data not shown). Flow
cytometric analysis of GBM CSCs cultured long-term without exoge-
nous mitogens demonstrated significantly decreased CD133+ cells and
CD133 expression and increased EGFR+ cells and EGFR expression
(Figures 3G andW2; P < .05 compared to standard growth conditions).
Figure 3. GBMCSCs propagate independent of exogenous EGF with increased activation of ERBB family receptors. Removal of exogenous
EGF and bFGF significantly reduced short-term (4 days) proliferation of NSCs and GBM CSCs (*P< .05), although the antiproliferative effect
was less in the GBMCSC lines compared to NSCs (A). Unlike NSCs that growth arrestedwithout addition of exogenous EGF and bFGF, GBM
CSCs continued to propagate in vitro as spheres (B). GBMCSCswithout exogenousmitogensmaintained expression of the stem cell marker
nestin (C: green; DAPI nuclear counterstain, blue),multilineage potential (D: βIII-tubulin/Tuj1, green; GFAP, red), and tumor initiation capacity
(E: 22 GBM CSC−EGF/−bFGF, 100,000 cells, 90 days). Flow cytometry analysis of GBM CSC−EGF/−bFGF demonstrated significantly de-
creased CD133 expression and increased EGFR expression (G: *P < .05). CD133 expression did not return on mitogen readdition and sub-
culture, whereas EGFR expression decreased (G). Immunoblot analysis demonstrated increased ERBB family activation (ERBB2, ERBB3)
and maintained downstream pAKT and pERK1/2 in GBM CSCs without EGF and bFGF compared to +EGF/+bFGF (F).
Figure 2. EGFR signaling components are present in GBMCSCs. Immunocytochemistry demonstrated expression of EGFR on both NSCs
(A) andGBMCSCs (B). EGFR expressionwas validated for all GBMCSC lines usingWestern immunoblot analysis (C), semiquantitative PCR
(D), and flow cytometry (E and F). Flow cytometry analysis showed presence of EGFR expression in all GBMCSC lines, although at varying
levels, and NSCs demonstrated a significantly higher percentage of EGFR+ cells compared to GBM CSCs (F). Presence of the common
EGFRvIII mutation was tested using semiquantitative RT-PCR and was not present in any of the isolated GBM CSC lines (D).
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CD133+ cells and CD133 expression did not recover for the GBMCSCs
after exogenous mitogen readdition and subculture, whereas EGFR+ cells
and EGFR expression was reduced (Figures 3G and W2). Altogether,
self-renewing multipotent GBM CSCs that were able to initiate tumors
survived and propagated after withdrawal of exogenous mitogens.
We used immunoblot analysis to analyze signaling within the GBM
CSCs (12.1 and 22) with and without exogenous EGF and bFGF in an
attempt to uncover mechanisms that allow continued growth of the
cells without exogenous mitogenic stimulation. Conceptually, these
mechanisms may represent inherent GBM CSC resistance to anti-
EGFR therapies. Not surprisingly, downstream activation of AKT
and ERK1/2 (MAPK) remained relatively constant with GBM CSC
culture with and without exogenous EGF (Figure 3E ). Multiple re-
ports have identified these downstream pathways as critical in GBM
and CSC survival and propagation [14,16,28,29,38]. Up-regulation
and activation of the ERBB family receptors ERBB2 and ERBB3 were
also observed after exogenous mitogen removal from GBM CSCs
(Figure 3E ), thereby suggesting that compensatory ERBB2/3 activa-
tion maintained downstream AKT and MAPK signaling in CSCs.
ERBB Family Signaling Is Required for
GBM CSC Proliferation
To test the contribution of ERBB2 to GBM CSC proliferation after
removal of exogenous EGF and bFGF, GBM CSC colony formation
assays after addition of the dual TKI lapatinib (blocks activation of both
EGFR and ERBB2) [39] were compared with cetuximab blockade of
EGFR alone. This experiment also addresses the possibility of endoge-
nous or autologous EGFR activation. Before colony formation assays,
immunoblot analysis was used to verify robust blockade of EGFR
activation using cetuximab (100 nM) and lapatinib (5 μM) in GBM
CSC lines (12.1 and 22 GBM CSCs +EGF/+bFGF; Figure W3). We
also verified that multiple monospecific EGFR inhibitors encompassing
blocking antibodies as well as TKIs failed to decrease downstreamEGFR
signaling (FigureW4). Addition of cetuximab (100 nM) [34,35] to GBM
CSCs with exogenous mitogens significantly reduced their colony-
forming ability compared to vehicle controls (68% ± 3.9% of control
for 22 CSC and 49% ± 3.2% for 12.1 CSC, P < .05; Figure 4). In
GBMCSCs cultured without exogenous EGF and bFGF, cetuximab’s
effect was greatly attenuated (89% ± 2.9% of control for 22 CSC and
89% ± 1.3% for 12.1 CSC, P < .05). Lapatinib (5 μM) [36,40,41]
strongly inhibited colony formation by GBMCSCs cultured in media
with or without exogenous EGF and bFGF (27%± 2.7% of control for
22 CSC and 13% ± 2.0% of control for 22 CSC −EGF; 9.7% ± 2.8%
for 12.1 CSC and 16% ± 4.8% for 12.1 CSC(−)EGF; P < .05; Fig-
ure 4). Lapatinib also successfully reduced downstream pAKT and
pERK1/2 signaling in 12.1 and 22GBMCSCs shown by immunoblot
analysis (Figure 4D). The effects of EGFR and ERBB2 inhibition were
also tested in four additional GBMCSC lines cultured in the presence
of EGF and bFGF. Cetuximab inhibited growth of all GBMCSC lines
(15, 33, 44, and 99) tested, decreasing colony formation from 19% to
43% compared to vehicle controls (P < .05). However, dual targeting
of EGFR and ERBB2 using lapatinib was significantly more effective
at inhibiting proliferation compared to cetuximab (67%-87% total re-
duction, P < .05). Immunoblot analysis demonstrated a range of
pAKT and pERK1/2 inhibition in these additional GBM CSC lines.
Discussion
Growth factor–stimulated RTK signaling, particularly aberrant EGF
receptor activation, is gaining much attention in both cancer and
CSC biology. Multiple TKIs and blocking monoclonal antibodies
Figure 4. Dual blockade of EGFR and ERBB2 prevents propagation of GBMCSCs. Cetuximab (inhibitory EGFR antibody, 100 nM) inhibited
colony-forming ability of GBM CSCs, but the effect is heavily attenuated in GBM CSCs without exogenous EGF and bFGF (A, B) (*P< .05).
Lapatinib (EGFR/ERBB2 TKI, 5 μM) inhibited colony formation by GBM CSCs from either growth condition equally (A, B). Lapatinib also
significantly better prevented colony formation in an additional four GBM CSC lines, compared to cetuximab (C). Immunoblot analysis
demonstrated reduced AKT activation with lapatinib after EGF stimulation, as well as reduced pERK1/2 in three of the GBM CSC lines
(22, 12.1, and 44) (D).
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are already in clinical use for various cancers such as lung, head/neck,
breast, colorectal, and others [10–12,42], with many second-generation
EGFR inhibitors also in clinical trials [43,44]. In brain tumors, EGFR is
overexpressed in up to 50% of GBMs [45] with the EGFR variant III
(EGFRvIII) mutation (confers constitutive EGF signaling) present in
up to 40% of EGFR-amplified GBMs [5,46]. Despite the seemingly
critical role of EGFR signaling in GBM, initial clinical trials have only
shownmodest improvements in a small percentage of patients [13–16].
These initial clinical results demonstrate the importance of under-
standing GBM resistance mechanisms to EGFR and other molecular
inhibitors toward developing more effective treatments.
Within GBM, the CSC subpopulation likely harbors intrinsic or
rapidly acquired resistance to EGFR inhibitors as for other chemother-
apeutics [26,27,47]. In this study, we removed exogenous mitogens
present in GBM CSC culture medium as a means of investigating
GBM CSC responses to disruption of EGFR signaling. We identified
activation of compensatory ERBB family members, specifically ERBB2
and ERBB3, in GBM CSCs deprived of exogenous EGF, suggesting
blockade of multiple ERBB family members is required for successful
GBM CSC eradication. This was shown through addition of lapatinib,
a dual TKI directed at EGFR and ERBB2, to effectively prevent GBM
CSC colony formation in all tested independent GBM CSC lines.
These results of EGFR blockade within GBMCSCs are in line with
and extend recently reported results [25,28,29]. Soeda et al. [28] tested
multiple growth factors for their ability to promote sphere formation in
three independent brain tumor lines and found that EGF stimulation
was required for sphere formation. In contrast, Kelly et al. [25] success-
fully generated CSC cultures from 8 of 11 GBM samples in the ab-
sence of exogenous mitogens (−EGF/−bFGF). Although timing of
the studies was different, as Soeda et al. [28] tested sphere formation
after 7 days and Kelly et al. [25] established ongoing cultures directly
from patient specimens, these studies suggest variable GBM CSC
growth factor requirements between samples. Our results for three es-
tablished GBM CSC lines correlates with the findings of Kelly et al.
[25]; when cultured without exogenous mitogens (EGF and bFGF),
GBM CSCs continued to self-renew and maintained multipotency
and tumor initiation capability. The comparison controls of normal
NSCs did not form spheres or survive without exogenous growth fac-
tors, in agreement with Kelly et al. [25], so growth factor–free survival
seems to be a CSC oncogenic property. In this study, we demonstrate
that continued GBM CSC propagation after EGF removal is at least
partially due to activation of ERBB family signaling. Our data along
with the reported studies suggest that EGFR signaling is required for
GBM CSC propagation, but the CSCs can rapidly activate related
RTKs to maintain downstream signaling pathways for survival.
Although not investigated in this study, it will be important to de-
termine the drivers of the compensatory ERBB signaling found in
GBM CSCs after EGF deprivation. Genetically, the constitutively ac-
tive EGFRvIII mutation was not identified in any of the GBM CSC
lines (Figure 2), and we have additionally demonstrated that the main
EGFRkinase domain abnormalities found in lung cancer are not present
in the tested GBM CSC lines (data not shown). Autocrine or paracrine
stimulation of EGFR through ligands such as EGF or amphiregulin,
among others, may also confer survival and proliferative cues to GBM
CSCs independent of exogenous EGF. These types of signaling may
explain the small but significant effect of cetuximab at inhibiting
GBMCSC colony formation in mediumwithout exogenous mitogens
(Figure 4); however, lapatinib treatment resulted in greater inhibition
of colony formation, suggesting that autocrine or paracrine EGFR
stimulation is only partially responsible for GBM CSC exogenous mi-
togen independence. Finally, multiple reports have now identified
neuregulin ligands as potential drivers in ERBB-dependent cancers
such as head and neck, colon, and lung [42,48]. Neuregulin ligands
activate ERBB family members ERBB3 or ERBB4 that dimerize with
other family members as well as activating their own downstream sig-
naling [49,50], and future work will need to determine the role of
neuregulins in GBM CSC growth and resistance to EGFR inhibitors.
The role of ERBB family signaling in resistance to molecular in-
hibitors is rapidly becoming appreciated in many forms of cancer
[34,42,51–53]. In glioma, the role of ERBB2 and ERBB3 signaling
in progression and resistance remains largely unknown. Some GBM
cell lines express ERBB2, including A172 and U251MG, and have
been shown to be sensitive either to ERBB2-inhibiting antibodies or
lapatinib [36,54]. Detection of ERBB2 in GBM and grade 3 gliomas
has also been reported, with low-ERBB2 expression correlated with a
better prognosis [55]. Early clinical trials have demonstrated reduced
pEGFR and pAKT after 7 days of lapatinib treatment in six of nine
patients tested; however, completion of the trial with reported survival
is still forthcoming [38].
Lastly, a caveat of the current study relates to lapatinib dosing. In
addition to specific EGFR- and ERBB2-targeted inhibition, other
“off-target” lapatinib activities have been reported—including inhibi-
tion of glutathione S -transferase P1 (GSTP1) [41], inhibition of
nuclear translocation of EGFR and ERBB2 [56], and inhibition of
sterol regulatory element-binding protein-1 (SREBP-1) to block fatty
acid synthesis [38]. Future studies will investigate the contribution
(if any) of these “nonspecific” lapatinib effects in targeting GBM
CSC proliferation.
In summary, this study provides an explanation for previous con-
founding reports showing the importance and necessity of aberrant
EGFR activation in GBMs, yet failure of EGFR-targeted inhibition
therapy in GBM clinical trials. We show that a subset of GBM cells,
the GBM CSCs, exhibit therapeutic resistance and proliferate despite
EGF deprivation or cetuximab-mediated EGFR inhibition through
compensatory activation of EGFR-related family members (ERBB2,
ERBB3). Importantly, only GBM CSCs proliferate, whereas normal
NSCs did not survive in the absence of EGFR signaling, implicating
ERBB2 and ERBB3 compensation in GBM CSCs as a tumorigenic
mechanism. The presence of this resistance mechanism in GBM
CSCs, which is able to recapitulate GBM, likely contributes to the
clinically observed rapid tumor recurrence and suggests that it is
worthwhile to explore multi-EGFR receptor family inhibition as a
component of more effective GBM treatment strategies.
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Table W1. Serial Dilution of GBM CSCs.
GBM CSCs Injected Mice with Tumors Days to Tumor
22 GBM CSC (+)EGF (+)bFGF 100,000 2/2 106
10,000 2/2 106
1000 2/2 112-169
100 3/3 125-188
12.1 GBM CSC (+)EGF (+)bFGF 100,000 2/2 96-109
10,000 2/2 109
1000 3/3 109-186
100 2/3 109-186
22 GBM CSC (−)EGF (−)bFGF 100,000 3/3 90-104
12.1 GBM CSC (−)EGF (−)bFGF 100,000 3/3 83
Figure W1. GBM CSCs initiate orthotopic xenografts exhibiting histological hallmarks of human GBM. Although 22 GBM CSCs initiated
mostly discrete tumors (A; Figure 1), tumor (T) cell invasion could be identified into the corpus callosum (CC) (C). The 33GBMCSC line initiated
highly diffuse tumors, visualized using a human-specific nestin antibody (hNestin), and tumor cells could be identified in the contralateral brain
(D, brown is hNestin+ cells). Frequent mitoses (E, arrowheads and inset) and nuclear atypia (F) were frequently seen in all GBM CSC-derived
xenografts. In some large GBM CSC–derived tumors, vascular proliferation (G, arrowheads) and areas of necrosis (H) were readily evident
(22 GBM CSC line). GBM CSCs cultured long term in medium −EGF/−bFGF did not lose tumor initiation capability (B).
Figure W2. GBM CSCs continued to form spheres and propagate in medium −EGF/−bFGF (B), appearing similar to GBM CSC spheres
grown in +EGF/+bFGF medium (A). In medium −EGF/−bFGF, GBM CSCs increased expression of EGFR (E, E1) and CD133 expression
was greatly reduced (D, D1), as demonstrated by flow cytometry. Readdition of mitogens and subsequent sphere formation (C) did not
increase CD133 expression in GBM CSCs (D2) but reduced EGFR levels (E2).
Figure W3. Lapatinib and cetuximab inhibit EGFR activation in GBM
CSC lines. After overnight exogenous mitogen removal and addition
of lapatinib (LAP, 5 μM)or cetuximab (CTX, 100 nM) for 2 hours, GBM
CSCs were stimulated for 30 minutes with EGF (20 ng/ml) before
protein collection. Subsequent immunoblot analysis demonstrated
robust inhibition of EGFR activation (tyrosine 1068 phosphorylation)
by both pharmacologic agents.
Figure W4.Monospecific EGFR inhibitorsdonot inhibit downstream
effectors of ERBB family signaling. 22 GBM CSCs were incubated
overnight with various EGFR-inhibiting agents: erlotinib (1 μM),
gefitinib (1 μM), cetuximab (100 nM), or pertuzumab (100 nM).
After protein collection, immunoblot analysis was performed to
examine ERBB family receptor activation and downstream signaling.
Minimal reduction in downstream AKT or ERK1/2 activation was ob-
served for all EGFR inhibitors tested. Treatment with monoclonal
blocking antibodies additionally resulted in activation of ERBB family
receptors ERBB2 and ERBB3.
